Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Choueiri, Toni K., Powles, Thomas, Burotto, Mauricio, Escudier, Bernard, Bourlon, Maria T., Zurawski, Bogdan, Oyervides Juárez, Victor M., Hsieh, James J. +23 more·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2026982

Cited by (1,000)

Items 101–200 of 1,000

A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma
Adele M. Alchahin, Shenglin Mei, Ιωάννα Τσέα, Taghreed Hirz, Youmna Sami Kfoury, Douglas M. Dahl, Chin‐Lee Wu, Alexander O. Subtelny, Shulin Wu, David T. Scadden et al. · 2022 · Nature Communications
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
Matthew Scott Ernst, Vishal Navani, John Connor Wells, Frede N. Donskov, Naveen S. Basappa, Chris Labaki, Sumanta Kumar Pal, Luís Meza, Lori Anne Wood, D. Scott Ernst et al. · 2023 · European Urology
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial
Nabil F. Saba, Conor Ernst Steuer, Asari Ekpenyong, Ashley A. McCook‐Veal, Kelly R. Magliocca, Mihir R. Patel, Nicole Cherie Schmitt, William A. Stokes, James E. Bates, Soumon F. Rudra et al. · 2023 · Nature Medicine
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Myung‐Chul Kim, Zeng Jin, Ryan H. Kolb, Nicholas C. Borcherding, Jonathan Alexander Chatzkel, Sara Moscovita Falzarano, Weizhou Zhang · 2021 · Cancers
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
Veronica Mollica, Matteo Santoni, Marc Ryan Matrana, Umberto Basso, Ugo De Giorgi, Alessandro Rizzo, Marco Maruzzo, Andrea Marchetti, Matteo Rosellini, Sara Bleve et al. · 2021 · Targeted Oncology
Single-cell transcriptomics reveals a low CD8 + T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma
Yulu Peng, Longbin Xiong, Zhaohui Zhou, Ning Kang, Zhen Li, Zeshen Wu, Min-Hua Deng, Wen-Su Wei, Ning Wang, Xiang-Peng Zou et al. · 2022 · Journal for ImmunoTherapy of Cancer
Clinically approved combination immunotherapy: Current status, limitations, and future perspective
Ligong Lu, Meixiao Zhan, Xian-Yang Li, Hui Zhang, Danielle J. Dauphars, Jun Jiang, Hua Yin, Shiyou Li, Sheng Luo, Yong Li et al. · 2022 · Current Research in Immunology
Stereotactic Ablative Radiation for Systemic Therapy–naïve Oligometastatic Kidney Cancer
Raquibul Hannan, Michael Christensen, Alana L. Christie, Aurélie Garant, Iván Pedrosa, Liliana Robles, Samantha Mannala, Chiachien Wang, Hans J. Hammers, Waddah Arafat et al. · 2022 · European Urology Oncology
The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors
Melissa Tian Bu, Pallavi Chandrasekhar, Lizhong Ding, Willy Hugo · 2022 · Pharmacology & Therapeutics
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
Grant Duncan Stewart, Sarah Joanne Welsh, Stephan Ursprung, Ferdia Aidan Gallagher, James O. Jones, Jacqui Shields, Christopher G. Smith, Thomas J. Mitchell, Anne Yvonne Warren, Axel Bex et al. · 2022 · British Journal of Cancer
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Thomas C. C. Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracián, Anthony B. El-Khoueiry, Bruno Sangro et al. · 2022 · Journal of Clinical Oncology
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
Lingbin Meng, Katharine Ann Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel J. Spakowicz, Linghua Zheng, Yuanquan Yang · 2023 · Cells
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Alexandre Ingels, Riccardo Campi, Umberto Capitanio A, Daniele Amparore, Riccardo Giuseppe Bertolo, Umberto Carbonara, Selçuk Erdem, Önder Kara, Tobias Klatte, MAXIMILIAN CHRISTIAN KRIEGMAIR et al. · 2022 · Nature Reviews Urology
Soluble PD-L1 as an early marker of progressive disease on nivolumab
Kathleen Margaret Mahoney, Petra Ross‐Macdonald, Long Yuan, Linan Song, Eliseo Veras, Megan Wind‐Rotolo, David F. McDermott, Frank Stephen Hodi, Toni K. Choueiri, Gordon James Freeman · 2022 · Journal for ImmunoTherapy of Cancer
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
Vito Amoroso, F. Gallo, Andrea Alberti, D. Paloschi, W. Ferrari Bravo, Assunta Esposito, Deborah Cosentini, Salvatore Grisanti, Rebecca Pedersini, Fausto Petrelli et al. · 2023 · ESMO Open
Targeted Therapies in Pheochromocytoma and Paraganglioma
Katharina Wang, Joakim Crona, Felix Beuschlein, Ashley Barry Grossman, Karel Pacák, Svenja Nölting · 2022 · The Journal of Clinical Endocrinology & Metabolism
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Pavlos Msaouel, Sangeeta Goswami, Peter F. Thall, Xuemei Wang, Ying Yuan, Eric W. Jonasch, Jianjun Gao, Matthew T. Campbell, Amishi Yogesh Shah, Paul Gettys Corn et al. · 2022 · Science Translational Medicine
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
Joel W. Neal, Nick Pavlakis, Sang‐We Kim, Yasushi Goto, Sun Min Lim, Giannis Mountzios, Elena Fountzilas, Anastasia S. Mochalova, Daniel Christian Christoph, Alessandra Bearz et al. · 2024 · Journal of Clinical Oncology
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
Matthew T. Campbell, Surena F. Matin, Alda Lui Tam, Rahul A. Sheth, Kamran Ahrar, Rebecca S. Slack Tidwell, Priya Rao, Jose Antonio Karam, Christopher G. Wood, Nizar M. Tannir et al. · 2021 · Nature Communications
Treatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination Therapy
Vishal Navani, Daniel Y.C. Heng · 2021 · JAMA Oncology
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
Ye Guo, Weijie Zhang, Jieer Ying, Yanqiao Zhang, Yueyin Pan, Wensheng Qiu, Qingxia Fan, Qi Xu, Yue Ma, Gang Wang et al. · 2022 · European Journal of Cancer
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Selina K. Wong, Caroline A. Nebhan, Douglas Buckner Johnson · 2021 · Frontiers in Immunology
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma
Giuseppe Procopio, Pierangela Sepe, Mélanie Claps, Sebastiano Buti, Maurizio Colecchia, Patrizia Giannatempo, Valentina Guadalupi, Luigi Mariani, Luca Lalli, Giovanni Fucà et al. · 2022 · JAMA Oncology
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Robert Motzer, Camillo Porta, B. Yа. Alekseev, Sun Young Rha, Toni K. Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C.H. Goh, Masatoshi Eto et al. · 2022 · The Lancet Oncology
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study
Lucía Carril-Ajuria, Aude Desnoyer, Maxime Meylan, Cécile Dalban, Marie Naigeon, Lydie Cassard, Yann Alexandre Vano, Nathalie C. Rioux-Leclercq, Salem Chouaı̈b, Benoit Beuselinck et al. · 2022 · Journal for ImmunoTherapy of Cancer
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, Hanna Bryant, Richard S. Kaplan, Babak Choodari‐Oskooei, Tom Powles, Grant Duncan Stewart, Laurence K. Albiges, Axel Bex et al. · 2021 · Contemporary Clinical Trials
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
Sarah Hamidi, Marie-Claude C. Hofmann, Priyanka Chandrasekhar Iyer, Maria E. Cabanillas, Mimi I-Nan Hu, Naifa Lamki Busaidy, Ramona Dadu · 2023 · Frontiers in Endocrinology
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio Gordan, Arash Rezazadeh Kalebasty et al. · 2021 · Cancer
Cabozantinib for the treatment of solid tumors: a systematic review
Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea Borghese Apolo, Santiago Viteri, Cristina Rodríguez‐Antona, Lidia Martín, Daniel Castellano · 2022 · Therapeutic Advances in Medical Oncology
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)
Chen Li, Yantao Tian, Yanan Zheng, Fei Yuan, Zheng Shi, Lin Yang, Hao Chen, Lixin Jiang, Xixun Wang, Ping Zhao et al. · 2024 · Journal of Clinical Oncology
A renal cell carcinoma tumorgraft platform to advance precision medicine
Roy M. Elias, Vanina Toffessi Tcheuyap, Akash Kaushik, Nirmish Singla, Ming Gao, Òscar Reig, Alana L. Christie, Aditi Mulgaonkar, Layton Woolford, Christina Stevens et al. · 2021 · Cell Reports
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
John B.A.G. Haanen, James Larkin, Toni K. Choueiri, Laurence K. Albiges, Brian I. Rini, Michael B. Atkins, Manuela Schmidinger, Konstantin Penkov, Elisabete Michelon, J. Wang et al. · 2023 · ESMO Open
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Yalan Zhang, Weilin Zhou, Jianping Yang, Jinrong Yang, Wei Wang · 2023 · Experimental Hematology and Oncology
Clinical development of immuno-oncology therapeutics
Jianxin Wang, Qi Chen, qiang Shan, Tingbo Liang, Patrick M. Forde, Lei Zheng · 2025 · Cancer Letters
Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions
Iris Tung, Arvind Sahu · 2021 · Frontiers in Oncology
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L. Bergmann, Laurence K. Albiges, Marit Ahrens, Marine Gross‐Goupil, Ekaterini Boleti, Gwénaëlle Gravis, Aude Fléchon, Marc‐Oliver Grimm, Jens Bedke, Philippe Barthélémy et al. · 2025 · Annals of Oncology
Strategies to overcome DC dysregulation in the tumor microenvironment
Guillaume Mestrallet, Kazuki Sone, Nina Bhardwaj · 2022 · Frontiers in Immunology
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Carlotta Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nolè, Francesco Carrozza et al. · 2022 · Tumori Journal
Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
Shawn Dason, Jahan Mohebali, Michael L. Blute, Keyan Salari · 2023 · Urologic Clinics of North America
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Anwaar Saeed, Robin Park, Harsh B. Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind A. Phadnis, Raed Moh’d Taiseer Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun et al. · 2024 · Nature Communications
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Olivier Alain Michielin, Aly‐Khan A. Lalani, Caroline Robert, Padmanee Sharma, Solange Peters · 2022 · Journal for ImmunoTherapy of Cancer
ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy
Wenjing Mo, Shujie Liu, Xiaozhi Zhao, Fayun Wei, Yuhang Li, Xinan Sheng, Wenmin Cao, Meng Ding, Wenlong Zhang, Xiaoqing Chen et al. · 2023 · Advanced Healthcare Materials
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience
Seo-Young Lee, Hyo Sup Shim, Beung‐Chul Ahn, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min Hee Hong · 2021 · Cancer Immunology Immunotherapy
Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Ruixi Wang, Shiliang Liu, Baoqing Chen, Mian Xi · 2022 · Cancers
French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer
Pierre Bigot, Philippe Barthélémy, R. Boissier, Z. Khene, Caroline Pettenati, Jean‐Christophe Bernhard, Jean-Michel Corréas, N. Doumerc, P. Gimel, Alexandre Ingels et al. · 2022 · The French Journal of Urology
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review
Bradley Alexander McGregor, Amir Mortazavi, Lisa M. Cordes, Cristina Salabao, Susan Vandlik, Andrea Borghese Apolo · 2021 · Cancer Treatment Reviews
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Miguel F. Sanmamed, Pedro Berraondo, Maria Esperanza Rodriguez-Ruiz, Ignacio Melero · 2022 · Nature Cancer
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma
G. Pignot, Antoine Thiery-Vuillemin, Laurence K. Albiges, Jochen Christoph Walz, Hervé Lang, L. Balssa, Bastien Parier, Lionnel Geoffrois, Karim Bensalah, Friederike Schlürmann et al. · 2022 · European Urology Oncology
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
Xiaofeng Chen, Hao Xu, Xiaobing Chen, Tongpeng Xu, Yitong Tian, Deqiang Wang, Fen Guo, Kangxin Wang, Guangfu Jin, Xiao Li et al. · 2024 · Signal Transduction and Targeted Therapy
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
Vincenzo Quagliariello, Massimiliano Berretta, Simona Buccolo, Martina Iovine, Andrea Paccone, Ernesta Cavalcanti, R. Taibi, Monica Montopoli, Gerardo Botti, Nicola Maurea · 2021 · Frontiers in Oncology
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Jimmy S. Patel, Yena Woo, Amber Draper, Caroline Stewart Jansen, Jennifer Wilkinson Carlisle, Pasquale F. Innominato, Françis Lévi, Layla Dhabaan, Viraj A. Master, Mehmet Asım Bilen et al. · 2024 · Journal for ImmunoTherapy of Cancer
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000–2025)
Liling Huang, Haohua Zhu, Yuankai Shi · 2025 · Journal of Hematology & Oncology
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
Yihui Pan, Guannan Shu, Liangmin Fu, Kangbo Huang, Xinwei Zhou, Chengpeng Gui, Huashan Liu, Xiaohan Jin, Minyu Chen, Pengju Li et al. · 2023 · Advanced Science
Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
Xianbin Wu, Runkun Han, Yanping Zhong, Nuoqing Weng, Ao Zhang · 2021 · Cancer Cell International
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy
Robert John Motzer, Manuela Schmidinger, Masatoshi Eto, Cristina Suárez, Robert A. Figlin, Yanfang Liu, Rodolfo F. Perini, Yayan Zhang, Daniel YC Heng · 2023 · Future Oncology
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
Zhishan Zhang, Qunxiong Pan, Mingdong Lu, Bin Zhao · 2023 · EClinicalMedicine
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
Femke H. Burgers, Johannes Cornelis van der Mijn, Tom T. P. Seijkens, Inge Jedema, Axel Bex, John B.A.G. Haanen · 2025 · Nature Reviews Nephrology
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
Niklas Klümper, Damian Johannes Ralser, Romina Zarbl, Katrin Schlack, Andres Jan Schrader, Marc Rehlinghaus, Michèle J. Hoffmann, Günter Niegisch, Annemarie Uhlig, Lutz Trojan et al. · 2021 · Journal for ImmunoTherapy of Cancer
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
Jens Bedke, Laurence K. Albiges, Umberto Capitanio A, Rachel H. Giles, Milan Hora, Thomas B. L. Lam, Börje Ljungberg, Lorenzo SO Marconi, Tobias Klatte, Alessandro Volpe et al. · 2021 · European Urology
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin War Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindřich Kopecký, Jakub Kucharz, Sebastiano Buti, Mimma Rizzo et al. · 2023 · Targeted Oncology
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Viktor Grünwald, Thomas B. Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert John Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung‐Hoo Hong et al. · 2023 · Frontiers in Oncology
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma
Alireza Ghoreifi, Ulka N. Vaishampayan, Ming Yin, Sarah P. Psutka, Hooman Djaladat · 2023 · JAMA Oncology
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
Matthew D. Tucker, Landon Carter Brown, Yu‐Wei Chen, Chester Kao, Nathan A. Hirshman, Emily Noelle Kinsey, Kristin Kathleen Ancell, Kathryn Eby Beckermann, Nancy B. Davis, Renee K. McAlister et al. · 2021 · Biomarker Research
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma
Matteo Santoni, Veronica Mollica, Alessandro Rizzo, Francesco Massari · 2025 · Cancer Treatment Reviews
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC
Fabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, Alessandro Samuelly, Maristella Bungaro, Marco Audisio, Chiara Pisano, Massimo Di Maïo, Giorgio V. Scagliotti, Consuelo Buttigliero · 2021 · Endocrine Related Cancer
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
Kathryn Eby Beckermann, Amita Patnaik, Ira Seth Winer, Winston W. Tan, Babar Bashir, Christos E. Kyriakopoulos, Randy F. Sweis, Marc Charles Chamberlain, Brian I. Rini · 2024 · Investigational New Drugs
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao · 2024 · Journal of Translational Medicine
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Areti D. Strati, Christos Adamopoulos, Ioannis Kotsantis, Amanda K. Psyrri, Evi S. Lianidou, Athanasios G. Papavassiliou · 2025 · International Journal of Molecular Sciences
Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma
Michael Thomas Serzan, Michael B. Atkins · 2021 · Journal of Cancer Metastasis and Treatment
New approaches to first-line treatment of advanced renal cell carcinoma
Daniel J. George, Chung‐Han Lee, Daniel Y.C. Heng · 2021 · Therapeutic Advances in Medical Oncology
State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma
Shawn Dason, Kristine Peregrino Lacuna, Raquibul Hannan, Eric A. Singer, Karie D. Runcie · 2023 · American Society of Clinical Oncology Educational Book
Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
Nina B. Curkovic, Kun Bai, Fei Ye, Douglas Buckner Johnson · 2024 · Cancers
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions
Saeed Rafii, Deborah Mukherji, Ashok Sebastian Komaranchath, Charbel Khalil, Faryal Iqbal, Siddig İbrahim Abdelwahab, Amin M. Abyad, Ahmad Y. Abuhelwa, Lakshmikanth Gandikota, Humaid Obaid Al-Shamsi · 2025 · Cancers
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
Joel Randolph Hecht, Young Suk Park, Josep M. Tabernero, Myung Ah Lee, Soo Hyun Lee, A.C. Virgili Manrique, Marc Van den Eynde, Elisa Fontana, Marwan Fakih, Gholamreza Asghari et al. · 2025 · The Lancet
FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity
Keqin Dong, Wenjin Chen, Xiuwu Pan, Hongru Wang, Ye Sun, Cheng Qian, Weijie Chen, Chao Wang, Yang Fu, Xingang Cui · 2022 · BMC Cancer
Rapid Profiling of Tumor‐Immune Interaction Using Acoustically Assembled Patient‐Derived Cell Clusters
Zheng Ao, Zhuhao Wu, Hongwei Cai, Liya Hu, Xiang Li, Connor Kaurich, Jackson Chang, Mingxia Gu, Liang Cheng C, Xin Lü et al. · 2022 · Advanced Science
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Elshad Hasanov, Debra Nana Yeboa, Mathew D. Tucker, Todd Allen Swanson, Thomas Hendrix Beckham, Brian I. Rini, Chibawanye Ene, Merve Hasanov, Sophie H. A. E. Derks, Marion Smits et al. · 2022 · CA A Cancer Journal for Clinicians
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
Jennifer Wilkinson Carlisle, Caroline Stewart Jansen, Maria Andrea Cardenas, Ewelina Sobierajska, Adriana Moon Reyes, Rachel Greenwald, Luke del Balzo, Nataliya Prokhnevska, Ömer Küçük, Bradley Curtis Carthon et al. · 2022 · Journal for ImmunoTherapy of Cancer
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
Angela Aldin, Burcu Besiroglu, Anne Adams, Ina Monsef, Vanessa Piechotta, Eve Tomlinson, Carolin Hornbach, Nadine Dressen, Marius Goldkuhle, Philipp Maisch et al. · 2023 · Cochrane Database of Systematic Reviews
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
Hannah Noelle Bell, Brittney H. Cotta, Simpa Samuel Salami, Hyung Lae Kim, Ulka N. Vaishampayan · 2021 · Kidney Cancer
Antibody-lectin chimeras for glyco-immune checkpoint blockade
Jessica C. Stark, Melissa Anne Gray, Itziar Ibarlucea-Benitez, Marta Lustig, Annalise Bond, Brian Cho, Ishika Govil, Tran Luu, Megan J. Priestley, Tim S. Veth et al. · 2025 · Nature Biotechnology
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
Matteo Santoni, Roberto Iacovelli, Valentina Colonna, Stephan G. Klinz, Giorgio Mauri, Marianna Nuti · 2021 · Expert Review of Anticancer Therapy
Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
Koji Iinuma, Torai Enomoto, Kei Kawada, Shota Fujimoto, Takashi Ishida, Kimiaki Takagi, Shingo Nagai, Hiroki Ito, Makoto Kawase, Chie Nakai et al. · 2021 · Journal of Clinical Medicine
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
Aly‐Khan A. Lalani, Daniel Y.C. Heng, Naveen S. Basappa, Lori Anne Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières, Christian Kollmannsberger · 2022 · Therapeutic Advances in Medical Oncology
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew Warren Hahn, Mehmet Asım Bilen, Pavlos Msaouel et al. · 2023 · The Oncologist
Vitamin A and retinoid signaling in the kidneys
Krysta M. DiKun, Lorraine J. Gudas · 2023 · Pharmacology & Therapeutics
Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic
Iben Lyskjær, Laura Iisager, Christian Tang Axelsen, Tommy Kjærgaard Nielsen, Lars Dyrskjøt, Niels Fristrup · 2023 · Clinical Cancer Research
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Toni K. Choueiri, Jaime Rafael Merchan, Robert A. Figlin, David F. McDermott, Edward R. Arrowsmith, Marc Dror Michaelson, Scott S. Tykodi, Elisabeth I. Heath, David Robert Spigel, Anishka D'souza et al. · 2025 · The Lancet Oncology
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies
Andrew James Wiele, Tharakeswara Kumar Bathala, Andrew Warren Hahn, Lianchun Xiao, Munevver Duran, Jeremy Aaron Ross, Eric W. Jonasch, Amishi Yogesh Shah, Matthew T. Campbell, Pavlos Msaouel et al. · 2021 · The Oncologist
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes
Pavlos Msaouel, Juhee Lee, Peter F. Thall · 2021 · Cancers
Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
Nikhita Kathuria‐Prakash, Claire E. Drolen, Christopher A. Hannigan, Alexandra Drakaki · 2021 · Life
Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Kelly N. Fitzgerald, Robert John Motzer, Chung‐Han Lee · 2022 · Nature Reviews Urology
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
Anwaar Saeed, Robin Park, Junqiang Dai, Raed Moh’d Taiseer Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Stephen K. Williamson, Azhar Saeed, Jacob Ripp, Zachary S. Collins et al. · 2023 · Cell Reports Medicine
Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
Georges Gebrael, Kamal Kant Sahu, Neeraj Agarwal, Benjamin Louis Maughan · 2023 · Human Vaccines & Immunotherapeutics
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Ishita Gupta, Ola Hussein, Konduru Seetharama Sastry, Salim Bougarn, Neha Gopinath, Evonne C. Chin-Smith, Yashi Sinha, Hesham Mohamed Korashy, Cristina Maccalli · 2023 · Advances in Cancer Biology - Metastasis
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
Matteo Santoni, Francesco Massari, Sergio Bracarda A, Enrique Grande, Marc Ryan Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia et al. · 2022 · European Urology Focus
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
Jonathan Thouvenin, Omar Alhalabi, Maria Isabel Carlo, Lucía Carril-Ajuria, Laure Hirsch, Nieves Martínez Chanzá, Sylvie Négrier, Luca Campedel, Dylan J. Martini, Delphine Borchiellini et al. · 2022 · The Oncologist
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Adriana Petrazzuolo, Maria Chiara Maiuri, Laurence Zitvogel, Guido Kroemer, Oliver Kepp · 2022 · OncoImmunology
Immune landscape and immunotherapy for penile cancer
Yaxiong Tang, Xu Hu, Kan Wu, Xiang Li · 2022 · Frontiers in Immunology
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Viktor Grünwald, Thomas B. Powles, Evgeny Kopyltsov, Vadim Viktorovich Kozlov, Teresa Alonso‐Gordoa, Masatoshi Eto, Thomas E. Hutson, Robert John Motzer, Eric Winquist, Pablo Maroto et al. · 2023 · European Urology Oncology